Evidence map›Paper›PMID 25222616›Full record

ArticlePloS one2014

Serum 8,12-iso-iPF2α-VI isoprostane marker of oxidative damage and cognition deficits in children with konzo.

Bumoko G Makila-Mabe, Kambale J Kikandau, Thérèse M Sombo, Daniel L Okitundu, Jean-Claude Mwanza, Michael J Boivin, Mumba D Ngoyi, Jean-Jacques T Muyembe, Jean-Pierre Banea, Gerard R Boss and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Observational
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Bumoko G Makila-MabeDepartment of Neurology, University of Kinshasa, Kinshasa, Congo-Kinshasa.
Kambale J KikandauDepartment of Biomedical Sciences, University of Kinshasa, Kinshasa, Congo-Kinshasa.
Thérèse M SomboDepartment of Neurology, University of Kinshasa, Kinshasa, Congo-Kinshasa.
Daniel L OkitunduDepartment of Neurology, University of Kinshasa, Kinshasa, Congo-Kinshasa.
Jean-Claude MwanzaDepartment of Ophthalmology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Michael J BoivinDepartment of Psychiatry and Neurology/Ophthalmology, Michigan State University, East Lansing, Michigan, United States of America.
Mumba D NgoyiDepartment of Tropical Medicine, University of Kinshasa, Kinshasa, Congo-Kinshasa; Department of Parasitology, Institut National de Recherches Biomédicales, Kinshasa, Congo-Kinshasa.
Jean-Jacques T MuyembeDepartment of Tropical Medicine, University of Kinshasa, Kinshasa, Congo-Kinshasa; Department of Parasitology, Institut National de Recherches Biomédicales, Kinshasa, Congo-Kinshasa.
Jean-Pierre BaneaDepartment of Nutrition, School of Public Health & National Nutrition Program, Ministry of Health, Kinshasa, Congo-Kinshasa.
Gerard R BossDepartment of Medicine, University of California San Diego, La Jolla, California, United States of America.
Desiré Tshala-KatumbayDepartment of Neurology, University of Kinshasa, Kinshasa, Congo-Kinshasa; Department of Neurology, Oregon Health & Science University, Portland, Oregon, United States of America; Oregon Institute of Occupational Health Sciences, Oregon Health & Science University, Portland, Oregon, United States of America.
University of Kinshasa · CDMichigan State University · USMinistry of Public Health · CDNational Institute of Biomedical Research · CDUniversity of California, San Diego · USUniversity of North Carolina at Chapel Hill · US

Funding

Pre-Clinical and Clinical Studies of Cobinamide, A New Cyanide Detoxifying AgentU01NS058030 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BOSS, GERRY R · 2006 to 2017
$7.3M
Toxicodietary and genetic determinants of susceptibility to neurodegenerationR01ES019841 · NIEHS · OREGON HEALTH & SCIENCE UNIVERSITY · PI TSHALA-KATUMBAY, DANIEL DESIRE · 2011 to 2020
$4.6M
NIEHS NIH HHS R01 ES019841NIEHS NIH HHS R01ES019841NINDS NIH HHS U01 NS058030
6 · The paper itself

Abstract

We sought to determine whether motor and cognitive deficits associated with cassava (food) cyanogenic poisoning were associated with high concentrations of F2-isoprostanes, well-established indicators of oxidative damage. Concentrations of serum F2-isoprostanes were quantified by LC-MS/MS and anchored to measures of motor proficiency and cognitive performance, which were respectively assessed through BOT-2 (Bruininks/Oseretsky Test, 2nd Edition) and KABC-II (Kaufman Assessment Battery for Children, 2nd edition) testing of 40 Congolese children (21 with konzo and 19 presumably healthy controls, overall mean age (SD): 9.3 (3.2) years). Exposure to cyanide was ascertained by concentrations of its main metabolite thiocyanate (SCN) in plasma and urine. Overall, SCN concentrations ranged from 91 to 325 and 172 to 1032 µmol/l in plasma and urine, respectively. Serum isoprostanes ranged from 0.1 to 0.8 (Isoprostane-III), 0.8 to 8.3 (total Isoprostane-III), 0.1 to 1.5 (Isoprostane-VI), 2.0 to 9.0 (total Isoprostane-VI), or 0.2 to 1.3 ng/ml (8,12-iso-iPF2α-VI isoprostane). Children with konzo poorly performed at the BOT-2 and KABC-II testing relative to presumably healthy children (p<0.01). Within regression models adjusting for age, gender, motor proficiency, and other biochemical variables, 8,12-iso-iPF2α-VI isoprostane was significantly associated with the overall cognitive performance (β = -32.36 (95% CI: -51.59 to -13.03; P<0.001). This model explained over 85% of variation of the KABC-II score in children with konzo, but was not significant in explaining the motor proficiency impairment. These findings suggest that cognitive deficits and, possibly, brain injury associated with cassava poisoning is mediated in part by oxidative damage in children with konzo. 8,12-iso-iPF2α-VI isoprostane appears to be a good marker of the neuropathogenic mechanisms of konzo and may be used to monitor the impact of interventional trials to prevent the neurotoxic effects of cassava cyanogenic poisoning.

Indexed as

CognitionOxidative StressBiomarkersChildChromatography, LiquidF2-IsoprostanesFemaleHumansMaleManihotTandem Mass SpectrometryThiocyanatesBiomarkersF2-IsoprostanesthiocyanateThiocyanates

Identifiers

PMID25222616
PMCPMC4164531
OpenAlexW2087328422

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.